Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA is Of Counsel at Health Law Alliance and a registered U.S. Patent Attorney

Frequently Asked Questions

Why is an Ozempic compliance program necessary?

Healthcare is a highly regulated industry, and an effective compliance program helps to reduce the risk of regulatory noncompliance.

What are the elements of an Ozempic compliance program?

Compliance programs typically include seven elements, including written policies and procedures; employee training and education; monitoring; and remedial action.

Who is responsible for administering an Ozempic compliance program?

Depending on the size of the business, compliance oversight may be performed by a designed Chief Compliance Officer, Compliance Committee, or Board of Directors. In smaller businesses, a Compliance Manager or Business Lead may perform the function.

Short Hills, NJ - Health Law Alliance is pleased to announce that Dr. Martha M. Rumore, a nationally recognized pharmacist-attorney and registered patent attorney, has joined the firm as Of Counsel. With over two decades of experience in FDA, DEA, Board of Pharmacy, and pharmaceutical intellectual property matters, Dr. Rumore brings exceptional depth to the firm’s healthcare and regulatory practice.

Dr. Rumore holds a Pharm.D. from St. John’s University, a J.D. from CUNY School of Law, a Master’s in Medical Communications and Drug Information from Long Island University, and an LLM in Intellectual Property from Benjamin N. Cardozo School of Law.  

She is admitted to the New York, New Jersey, and D.C. bars, and is a Fellow of the American Pharmacists Association.

For the past six years, Dr. Rumore served as Senior Counsel at Frier Levitt in Manhattan, where she focused on FDA regulatory, DEA enforcement, Board of Pharmacy compliance, and pharmaceutical IP matters. Her expertise includes 503A and 503B compounding (including GLP-1s and peptides), DSCSA compliance, recalls, clinical trial management, labeling and advertising review, and submissions ranging from 510(k) to PMA applications.

Dr. Rumore has also held leadership positions in industry, including as Associate Director of Medical Affairs at Glenbrook Laboratories/Sterling Drug. She has taught Drug Regulatory Affairs and Food, Drug & Cosmetic Law at multiple institutions, including Hofstra University’s Maurice A. Deane School of Law. With over 200 publications and presentations, she is a frequent national lecturer on FDA and pharmacy law topics.

“Martha is a powerhouse addition to our team,” said Health Law Alliance founder Anthony Mahajan. “Her unique combination of pharmacy practice, legal expertise, and regulatory insight further strengthens our ability to defend pharmacies, providers, and healthcare organizations nationwide.”

To contact Dr. Martha Rumore, please call 800-345-4125 or fill out the form on this page.

Read more about Health Law Alliance's compounding pharmacy services here.

MORE ARTICLES BY CATEGORY

Get a Free Consultation

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

Defeating Optum: How HLA Won Full Termination Reversals for 7 New York Pharmacies

Health Law Alliance successfully reversed pending terminations for 7 New York pharmacies. Read more about how our PBM audit team achieved this stunning reversal.

Read More >>

Ketamine Marketing Risks for Mental Health Providers

Ketamine marketing is under increasing regulatory scrutiny, with providers facing risk over claims, off-label promotion, and patient targeting. Even well-intentioned messaging can trigger audits or enforcement if it crosses compliance lines.

Read More >>

Why PBMs are Investigating Provider-Patient Relationships—And What it Means for Your Pharmacy

PBMs are ramping up audit pressure in 2026, now targeting provider-patient relationships to justify recoupments and even network terminations. Without precise documentation, even well-established prescriptions can put pharmacies at serious financial and operational risk.

Read More >>

HLA Wins Full Reversal of PBM Credentialing Denial for an Independent Pharmacy

This week, Health Law Alliance achieved full reversal of a PBM credentialing denial for a New York pharmacy—mere weeks after it received a termination notice. Read more to learn how Health Law Alliance’s tireless advocacy can help your pharmacy in credentialing disputes.

Read More >>